Results from a multinational phase II study have shown that treatment with the caspase inhibitor GS-9450 can reduce markers of liver damage in patients with nonalcoholic steatohepatitis (NASH -- the most serious form of non-alcoholic liver disease) as demonstrated by reduced levels of alanine (ALT) and aspartate aminotransferases (AST), hepatic enzymes that indicate cell damage.